Physician profile
Augustine Munoz
NPI 1205861523
$2,338.29
in general payments reported to CMS, 2019-2025
31 companies · $492 in 2025
The $492 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $156 · 2021: $170 · 2022: $236 · 2023: $409 · 2024: $443 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002 · Education: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.85 |
| Education | $341.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $903.27 | 2019-2025 | Cresemba, Ambisome |
| United Therapeutics Corporation | $147.82 | 2024 | Tyvaso |
| Astrazeneca Pharmaceuticals Lp | $138.81 | 2020-2025 | Fasenra, Tagrisso |
| Actelion Pharmaceuticals US, INC. | $135.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $125.12 | 2020-2023 | Zerbaxa, Recarbrio |
| Pfizer INC. | $94.21 | 2019-2021 | |
| Abbvie INC. | $69.41 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $60.87 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $60.36 | 2019 | |
| Advanced Respiratory, INC | $53.13 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.00 | 2019-2025 | Jascayd |
| Glaxosmithkline, LLC. | $51.19 | 2022 | |
| Janssen Pharmaceuticals, INC | $40.84 | 2020-2023 | Xarelto |
| Insmed, INC. | $38.51 | 2019-2020 | |
| Genzyme Corporation | $35.19 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.33 | 2024-2025 | Lifevest |
| Emd Serono, INC. | $26.82 | 2022 | |
| Bard Access Systems, INC. | $25.02 | 2019 | |
| Viiv Healthcare Company | $24.93 | 2021 | |
| Alkermes, INC. | $24.26 | 2019 | |
| Calliditas Therapeutics US INC. | $22.04 | 2025 | Tarpeyo |
| Xeris Pharmaceuticals, INC. | $20.70 | 2025 | Gvoke Hypopen |
| Clovis Oncology, INC. | $20.60 | 2020 | |
| Mayne Pharma Commercial LLC | $19.54 | 2020 | |
| Amgen INC. | $19.33 | 2025 | Tavneos |
| Coloplast Corp | $17.87 | 2021 | |
| Epizyme, INC. | $17.69 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.68 | 2022 | |
| Sobi, INC | $16.66 | 2022 | |
| Allergan, INC. | $16.07 | 2019 | |
| Lilly USA, LLC | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustine Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.